This short article describes how Organovo is using a novel technology called bioprinting to produce liver and kidney tissues that could help reshape the way drugs are tested and organs are transplanted in our days. It also discusses the challenges and potential effects on society.
Roche, the Swiss pharmaceuticals giant, is caught in a race against time. After making a big bet on breakthrough drugs and personalized medicine, the company has spent much of the last 18 months thinking ahead to the challenges that machine learning and artificial intelligence pose to a traditional, integrated pharmaceutical business model.
How machine learning is revolutionizing the drug discovery process and saving $$$
After the boom of Blockbuster(drugs with revenues exceeding $1B/yr) approvals in the 90’s, there has been a slowdown in the development of new drug entities (NDE). With drugs already in the market for easy to identify targets, research in academia […]
Machine learning has been touted as a potential cure-all for high drug prices. A number of leading biopharmaceutical companies like Roche have made some large bets in using artificial intelligence tools to improve drug development, but it remains to be seen if machine learning is living up to its hype.
GSK is rethinking its drug discovery pipeline using machine learning